Literature DB >> 25428658

Healthcare resource utilization among patients diagnosed with idiopathic pulmonary fibrosis in the United States.

Ning Wu1, Yanni F Yu, Chien-Chia Chuang, Rosa Wang, Nicole N Benjamin, David B Coultas.   

Abstract

OBJECTIVES: Few studies have characterized healthcare resource utilization among patients with idiopathic pulmonary fibrosis. The objective of this study is to assess healthcare resource utilization among patients with idiopathic pulmonary fibrosis as compared to members without this condition.
METHODS: Patients newly diagnosed with idiopathic pulmonary fibrosis were identified from a national administrative claims database (2006-2011) as having ≥ 2 claims with idiopathic fibrosing alveolitis, or ≥ 1 claim with idiopathic fibrosing alveolitis and ≥ 1 claim with post-inflammatory pulmonary fibrosis (earliest claim with idiopathic fibrosing alveolitis denoted the index date), a procedure of lung biopsy or high-resolution computed tomography within ± 90 days of the index date, 12-month pre-index continuous enrollment, plus ≥ 2 confirmatory idiopathic fibrosing alveolitis diagnoses after the procedure. For each idiopathic pulmonary fibrosis patient, three members without the condition were matched by age/gender/region/payer type. Demographic/clinical characteristics were measured during the 1-year pre-index period. Healthcare resource utilization was assessed by quarter during 1-year pre- and post-index periods. Generalized estimating equation models controlling for patient characteristics were constructed to estimate adjusted post-index healthcare resource utilization.
RESULTS: In total, 1735 patients with idiopathic pulmonary fibrosis and 5205 without (mean age = 71.5 years; 46.1% female) were included. Adjusted results revealed idiopathic pulmonary fibrosis patients were more likely to use healthcare resources than members without the condition 1-year post-index (number of hospitalizations, emergency room visits, and outpatients visits: 0.63 vs 0.31, 0.62 vs 0.48, and 5.7 vs 3.1 per person-year, respectively).
CONCLUSIONS: Healthcare resource utilization is considerably higher among patients with idiopathic pulmonary fibrosis than members without the condition. Effective treatments for patients with idiopathic pulmonary fibrosis are needed to help reduce burden of healthcare resource use.

Entities:  

Keywords:  Comorbidity; Economic burden; Healthcare resource utilization; Idiopathic pulmonary fibrosis; Retrospective observational study

Mesh:

Year:  2015        PMID: 25428658     DOI: 10.3111/13696998.2014.991789

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  10 in total

Review 1.  Identification of Key Cost Generating Events for Idiopathic Pulmonary Fibrosis: A Systematic Review.

Authors:  Shalvaree Vaidya; Clare L Hibbert; Elizabeth Kinter; Stefan Boes
Journal:  Lung       Date:  2016-11-19       Impact factor: 2.584

2.  Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.

Authors:  William M Reichmann; Yanni F Yu; Dendy Macaulay; Eric Q Wu; Steven D Nathan
Journal:  BMC Pulm Med       Date:  2015-12-29       Impact factor: 3.317

3.  Mechanical ventilation in idiopathic pulmonary fibrosis: a nationwide analysis of ventilator use, outcomes, and resource burden.

Authors:  Joshua J Mooney; Karina Raimundo; Eunice Chang; Michael S Broder
Journal:  BMC Pulm Med       Date:  2017-05-22       Impact factor: 3.317

4.  The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review.

Authors:  Alex Diamantopoulos; Emily Wright; Katerina Vlahopoulou; Laura Cornic; Nils Schoof; Toby M Maher
Journal:  Pharmacoeconomics       Date:  2018-07       Impact factor: 4.981

5.  Clinical and economic burden of idiopathic pulmonary fibrosis in Quebec, Canada.

Authors:  Jean-Eric Tarride; Robert B Hopkins; Natasha Burke; Jason R Guertin; Daria O'Reilly; Charlene D Fell; Genevieve Dion; Martin Kolb
Journal:  Clinicoecon Outcomes Res       Date:  2018-02-22

6.  Forced Vital Capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis.

Authors:  Mariann I Lassenius; Iiro Toppila; Nora Pöntynen; Laura Kasslin; Jaana Kaunisto; Maritta Kilpeläinen; Tarja Laitinen
Journal:  Eur Clin Respir J       Date:  2019-12-17

7.  Impact of Idiopathic Pulmonary Fibrosis on Longitudinal Health-care Utilization in a Community-Based Cohort of Patients.

Authors:  Erica Farrand; Carlos Iribarren; Eric Vittinghoff; Tory Levine-Hall; Brett Ley; George Minowada; Harold R Collard
Journal:  Chest       Date:  2020-07-24       Impact factor: 9.410

8.  Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study.

Authors:  Karina Raimundo; Eunice Chang; Michael S Broder; Kimberly Alexander; James Zazzali; Jeffrey J Swigris
Journal:  BMC Pulm Med       Date:  2016-01-05       Impact factor: 3.317

9.  Impact of angiotensin II type 1 and G-protein-coupled Mas receptor expression on the pulmonary performance of patients with idiopathic pulmonary fibrosis.

Authors:  Débora Raupp; Renata Streck Fernandes; Krist Helen Antunes; Fabíola Adélia Perin; Katya Rigatto
Journal:  Peptides       Date:  2020-08-07       Impact factor: 3.750

10.  Increased respiratory morbidity in individuals with interstitial lung abnormalities.

Authors:  Nils Hoyer; Laura H Thomsen; Mathilde M W Wille; Torgny Wilcke; Asger Dirksen; Jesper H Pedersen; Zaigham Saghir; Haseem Ashraf; Saher B Shaker
Journal:  BMC Pulm Med       Date:  2020-03-19       Impact factor: 3.317

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.